The growing strength of the cardiovascular and renal benefits of established GLP-1 mimetics add another string to their bow in the management of T2DM, with cardiovascular disease (CVD) being the number one cause of death in patients with T2DM (147). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.